Yi-Qi-Zeng-Min-Tang, a Chinese medicine, ameliorates insulin resistance in type 2 diabetic rats

AIM: To investigate the effects of the Chinese herbal decoction, Yi-Qi-Zeng-Min-Tang (YQZMT), on insulin resistance in type 2 diabetic rats. METHODS: Sprague-Dawley rats were divided into two dietary regiments by feeding either normal pellet diet (NPD) or high fat diet (HFD). Four weeks later, the HFD-fed rats were injected intraperitoneally with low-dose streptozotocin (STZ). Rats with non-fasting blood glucose level >= 16.67 mmol/L were considered type 2 diabetic and further divided into five subgroups: the type 2 diabetes model group, low-close, medium-dose and high-dose YQZMT groups, and rosiglitazone group. Age-matched NPD-fed rats served as controls. YQZMT or rosiglitazone were administered for 8 wk. Intrapentoneal glucose and insulin tolerance tests were performed before and after the treatment to measure the glucose tolerance and insulin sensitivity. Serum levels of biochemical parameters, adipocytokines, such as tumor necrosis factor-a (TNF-alpha), interleukin-6 (IL-6), as well as free fatty acids (FFAs), were also analyzed. RESULTS: There was significant elevation of insulin resistance and serum levels of fasting glucose (12.82 +/- 1.08 mmol/L vs 3.60 +/- 0.31 mmol/L, P < 0.01), insulin (7197.36 +/- 253.89 pg/mL vs 4820.49 +/- 326.89 pg/mL, P < 0.01), total cholesterol (TC) (8.40 +/- 0.49 mmol/L vs 2.14 +/- 0.06 mmol/L, P < 0.01), triglyceride (2.24 +/- 0.12 mmol/L vs 0.78 +/- 0.05 mmol/L, P < 0.01), low-density lipoprotein cholesterol (LDL-c) (7.84 +/- 0.51 mmol/L vs 0.72 +/- 0.04 mmol/L, P < 0.01) and decrease in high-density lipoprotein cholesterol (HDL-c) (0.57 +/- 0.03 nrimol/L vs 1.27 +/- 0.03 mmol/L, P < 0.01) in the low-dose STZ and high-fat diet induced type 2 diabetic group when compared with the control group. Administration of YQZMT induced dose- and time-dependent changes in insulin resistance, glucose and lipid profile, and reduced levels of FFA, TNF-alpha and IL-6 in the type 2 diabetic rats. After the treatment, compared with the diabetic group, the insulin resistance was ameliorated in the high-dose YQZMT (2.82 g/100 g per day) group, with a significant reduction in serum glucose (12.16 +/- 1.00 mmol/L vs 17.65 +/- 2.22 mmol/L, P < 0.01), homeostasis model assessment of basal insulin resistance (22.68 +/- 2.37 vs 38.79 +/- 9.02, P < 0.05), triglyceride (0.87 +/- 0.15 mmol/L vs 1.99 +/- 0.26 mmol/L, P < 0.01), TC (3.31 +/- 0.52 mmol/L vs 6.50 +/- 1.04 mmol/L, P < 0.01) and LDL-c (2.47 +/- 0.50 mmol/L vs 6.00 +/- 1.07 mmol/L, P < 0.01), and a significant increase in HDL-c (0.84 +/- 0.08 mmol/L vs 0.50 +/- 0.03 mmol/L, P < 0.01). But the body weight was not changed significantly. CONCLUSION: YQZMT, which ameliorates insulin resistance and does not cause increase in body weight, may be a suitable therapeutic adjunct for the treatment of type 2 diabetes. (C) 2011 Baishideng. All rights reserved.